Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Intellectual Property Assets Strengthened for Cancer Immunotherapy Program
and for Marburg Virus and HIV Vaccines
ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company's intellectual property assets.
David Dodd, GeoVax President and CEO, commented, "These patent actions add to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 115 granted or pending patent applications spread over 24 patent families. Our development priorities continue to be our next-generation Covid-19 vaccine, currently in Phase 2 clinical trials, and our cancer immunotherapy program, with Gedeptin® as our lead product in a Phase 1/2 clinical trial for advanced head and neck cancer. Beyond these two programs, we continue to investigate MVA as a cancer immunotherapy platform, as it has shown interesting potential to address multiple cancer indications."
Mr. Dodd continued, "Although not currently under active development, our HIV program forms an important part of the dataset underpinning all of our MVA-based development programs. The patent protection associated with this vaccine is an important part of this technology platform. Also, our team is committed to supporting the successful advancement of vaccines against lethal hemorrhagic fever viruses such as Marburg virus, as we recognize the critically important medical and biodefense need, reflected by the inclusion of Marburg virus in the FDA Priority Review Voucher program."
Posted In: GOVX